Terms: = Ovarian cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
36 results:
1. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mtor signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive pan-cancer analysis of expression profiles and prognostic significance for NUMB and NUMBL in human tumors.
Zhang Y; Yang H; Liu W; Song Q; Li Y; Zhang J; Zhou D; Li A
Medicine (Baltimore); 2023 Sep; 102(35):e34717. PubMed ID: 37657045
[TBL] [Abstract] [Full Text] [Related]
3. Pan-cancer Analysis Reveals cancer-dependent Expression of SOX17 and Associated Clinical Outcomes.
Xu LI; Bai Y; Cheng Y; Sheng X; Sun D
Cancer Genomics Proteomics; 2023; 20(5):433-447. PubMed ID: 37643784
[TBL] [Abstract] [Full Text] [Related]
4. UQCRFS1 serves as a prognostic biomarker and promotes the progression of ovarian cancer.
Sun Q; Li J; Dong H; Zhan J; Xiong X; Ding J; Li Y; He L; Wang J
Sci Rep; 2023 May; 13(1):8335. PubMed ID: 37221238
[TBL] [Abstract] [Full Text] [Related]
5. Pulmonary benign metastasizing leiomyoma in patients aged 45 years and younger: clinical features and novelty in treatment.
Su H; Fan R; Yang H; You Y; Zhu L; Feng F
BMC Pulm Med; 2023 May; 23(1):168. PubMed ID: 37189093
[TBL] [Abstract] [Full Text] [Related]
6. Hypoxia-induced miR-9 expression promotes ovarian cancer progression via activating PI3K/AKT/mtor/GSK3β signaling pathway.
Zhu WJ; Huang HH; Feng YF; Zhan L; Yang J; Zhu L; Wang QY; Wei B; Wang WY
Neoplasma; 2023 Apr; 70(2):216-228. PubMed ID: 36964721
[TBL] [Abstract] [Full Text] [Related]
7. Advances in ovarian cancer Treatment Beyond PARP Inhibitors.
Aliyuda F; Moschetta M; Ghose A; Sofia Rallis K; Sheriff M; Sanchez E; Rassy E; Boussios S
Curr Cancer Drug Targets; 2023; 23(6):433-446. PubMed ID: 36757037
[TBL] [Abstract] [Full Text] [Related]
8. Validation of ESM1 Related to ovarian cancer and the Biological Function and Prognostic Significance.
Li YK; Zeng T; Guan Y; Liu J; Liao NC; Wang MJ; Chen KX; Luo XY; Chen CY; Quan FF; Wang J; Zhang QF; Zou J
Int J Biol Sci; 2023; 19(1):258-280. PubMed ID: 36594088
[No Abstract] [Full Text] [Related]
9. The roles and mechanisms of circular RNAs related to mtor in cancers.
Cao C; Wang Y; Wu X; Li Z; Guo J; Sun W
J Clin Lab Anal; 2022 Dec; 36(12):e24783. PubMed ID: 36426933
[TBL] [Abstract] [Full Text] [Related]
10. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
Farah AM; Gu S; Jia Y
Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
[TBL] [Abstract] [Full Text] [Related]
11. Deubiquitinase OTUD5 modulates mtorC1 signaling to promote bladder cancer progression.
Hou T; Dan W; Liu T; Liu B; Wei Y; Yue C; Que T; Ma B; Lei Y; Wang Z; Zeng J; Fan Y; Li L
Cell Death Dis; 2022 Sep; 13(9):778. PubMed ID: 36085200
[TBL] [Abstract] [Full Text] [Related]
12. Adult Granulosa Cell Tumor With Sarcomatous Transformation: A Case Study With Emphasis on Molecular Alterations.
Dahoud W; Handler J; Parimi V; Meyer CF; Wethington SL; Eshleman JR; Vang R; Ronnett BM; Xing D
Int J Gynecol Pathol; 2022 Nov; 41(6):600-607. PubMed ID: 34856571
[TBL] [Abstract] [Full Text] [Related]
13. A novel biomarker, MRPS12 functions as a potential oncogene in ovarian cancer and is a promising prognostic candidate.
Qiu X; Guo D; Du J; Bai Y; Wang F
Medicine (Baltimore); 2021 Feb; 100(8):e24898. PubMed ID: 33663122
[TBL] [Abstract] [Full Text] [Related]
14. Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Considine DPC; Jia G; Shu X; Schildkraut JM; Pharoah PDP; Zheng W; Kar SP;
Gynecol Oncol; 2021 Feb; 160(2):506-513. PubMed ID: 33246661
[TBL] [Abstract] [Full Text] [Related]
15. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract] [Full Text] [Related]
16. Bufalin inhibits ovarian carcinoma via targeting mtor/HIF-α pathway.
Su S; Dou H; Wang Z; Zhang Q
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
[TBL] [Abstract] [Full Text] [Related]
17. miRNA profile in ovarian cancer.
Ghafouri-Fard S; Shoorei H; Taheri M
Exp Mol Pathol; 2020 Apr; 113():104381. PubMed ID: 31954715
[TBL] [Abstract] [Full Text] [Related]
18. Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer.
Yang M; Zhai Z; Zhang Y; Wang Y
Arch Gynecol Obstet; 2019 Sep; 300(3):703-710. PubMed ID: 31197441
[TBL] [Abstract] [Full Text] [Related]
19. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract] [Full Text] [Related]
20. Clinical associations between ASCT2 and p‑mtor in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract] [Full Text] [Related]
[Next]
